NOC vs RPRX · P/E 17, rev $20.76B vs P/E 15, rev $1.30B
Northrop Grumman Corporation (NOC) versus Royalty Pharma Plc (RPRX) — a side-by-side from cached financials, not a winner call.
Northrop Grumman Corporation (NOC) is a aerospace & defense company listed on NYSE.
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
Latest reported NOC revenue for 2026-06-30 was $20.76B. Net income was $1.97B. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
Latest reported RPRX revenue for 2026-06-30 was $1.30B. Net income was $312.6M. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
NOC currently screens at market cap $78.14B and trailing P/E 17.2. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
Not investment advice. Open the NOC and RPRX stock pages for the full models.
Not investment advice.